6 results
8-K
EX-99.2
PASG
Passage Bio Inc
4 Mar 24
Passage Bio Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Recent Business Highlights
7:02am
Safety* Efficacy / Target Engagement Interim data demonstrates PBFT02 potential for best-in-class efficacy at the low dose In all patients, Dose 1 … observed related to ICM injection BIOMARKERS Evidence of target engagement with2-3x normal* levels of CSF progranulin in all participants on Day 30
8-K
EX-99.1
PASG
Passage Bio Inc
5 Jan 24
Regulation FD Disclosure
4:05pm
ranged from 2 to 6 months post-dosing as of data cutoff of Jan 3, 2024 Safety* Efficacy / Target Engagement Interim data demonstrates PBFT02 potential … sinus thrombosis No evidence of DRG toxicity No complications observed related to ICM injection BIOMARKERS Evidence of target engagement with 3.6-6.6
8-K
EX-99.3
PASG
Passage Bio Inc
7 Aug 23
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
7:15am
Continued interactions with regulatory authorities as data set matures to align on design of confirmatory study and pathway to Biologics License Application Continue engagement with regulatory authorities
Q&A
8-K
EX-99.1
PASG
Passage Bio Inc
3 Mar 21
Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
7:01am
and engagement efforts, including:
Sponsorship of ScreenPlus pilot program, in which GM1 has been added to the New York newborn screening pilot program … program to encourage early diagnosis of GM1 and to provide educational information to patients and clinicians regarding clinical trials.
Engagement
S-1
EX-3.3
PASG
Passage Bio Inc
3 Feb 20
IPO registration
6:39am
or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
8.3 Stock Certificates; Partly Paid Shares.
(a) The shares
DRS
EX-3.3
we563xnpad9ca
6 Dec 19
Draft registration statement
12:00am
- Prev
- 1
- Next